title: Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis.
abstract: OBJECTIVE
  Soluble receptor activator of nuclear factor-kappa B ligand (sRANKL) to osteoprotegerin ratio is designated as a bone metabolism equation in many rheumatologic disorders and would be modified with fish oil (FO) supplementation.
  
  
  METHODS
  Eighty-three females with rheumatoid arthritis were divided randomly to 40 and 43 patients treated with (1 g/day) or without FO for 3 months accompanied with conventional drugs, respectively. Osteoprotegerin, sRANKL, tumor necrosis factor alpha (TNFalpha) serum levels were measured before and after treatment.
  
  
  RESULTS
  Serum levels of osteoprotegerin increased, although sRANKL, TNFalpha and sRANKL/osteoprotegerin ratio decreased with FO therapy. A significant positive correlation was observed between sRANKL/osteoprotegerin ratio and TNFalpha levels (r=0.327, p=0.040) in the FO-treated group.
  
  
  CONCLUSIONS
  FO could decrease the inflammatory response by lowering of serum TNFalpha levels and sRANKL/osteoprotegerin ratio.
authors.affiliation: Biochemistry Laboratory, Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Sousan
authors.initials: S
authors.lastname: Kolahi
authors.forename: Amir
authors.initials: A
authors.lastname: Ghorbanihaghjo
authors.forename: Samira
authors.initials: S
authors.lastname: Alizadeh
authors.forename: Nadereh
authors.initials: N
authors.lastname: Rashtchizadeh
authors.forename: Hassan
authors.initials: H
authors.lastname: Argani
authors.forename: Ali-Reza
authors.initials: AR
authors.lastname: Khabazzi
authors.forename: Mehrzad
authors.initials: M
authors.lastname: Hajialilo
authors.forename: Elham
authors.initials: E
authors.lastname: Bahreini
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000178:diet therapy; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D019587:Dietary Supplements; D004311:Double-Blind Method; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D005395:Fish Oils / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood*; D010919:Placebos; D053245:RANK Ligand / Q000097:blood*; D012995:Solubility; D055815:Young Adult
chemical_list: D005395:Fish Oils; D053244:Osteoprotegerin; D010919:Placebos; D053245:RANK Ligand; C506030:TNFRSF11B protein, human